For the roughly 230,000 people in the United States and Europe living with chronic hepatitis D — one of the most aggressive forms of viral liver disease — treatment options have been painfully thin. On Monday, that picture got brighter. Mirum Pharmaceuticals announced that its experimental drug brelovitug met the main goal of a late-stage study, sharply reducing virus levels in patients.

Results like this don’t just move a stock price. They move the horizon for patients.

The announcement

Mirum said the Phase 3 portion of its AZURE-1 study hit its primary endpoint: virologic response plus normalization of liver enzymes at 24 weeks, in both dose groups. The numbers, reported by the company on September 28:

• 56% of patients on the 300-milligram dose achieved both a reduction in hepatitis D virus and normal liver enzyme levels.
• 45% on the 900-milligram dose hit the same mark.
• 0% in the delayed-treatment comparison group did.

Treatment was described as well tolerated across dose groups, with a safety profile consistent with previously reported data and no new safety signals. The company also reported encouraging 48-week data from the Phase 2b portion of AZURE-1, showing viral suppression deepening — and ALT normalization rates increasing — with longer treatment.

Full results will be presented at an upcoming medical congress, and Mirum expects to submit a marketing application (a biologics license application) to the U.S. Food and Drug Administration in the first half of 2027. AZURE-1 is one of two pivotal Phase 3 studies intended to form the basis of that registration package; topline results from the second, AZURE-4, are expected later this year.

What is hepatitis D — and why is it so hard to treat?

Hepatitis D is a cruel quirk of virology. The delta virus can only infect people who are already infected with hepatitis B. It hijacks the hepatitis B surface antigen — a protein on the virus’s outer shell — to assemble itself.

That dependency makes it both dangerous and difficult. Chronic hepatitis D can cause severe symptoms and progress to liver damage, cirrhosis, and death faster than other forms of viral hepatitis. And because the virus is essentially a parasite of another virus, standard antivirals aimed at viral replication often miss it. The company estimates it affects about 230,000 people in the U.S. and Europe.

How brelovitug works

Brelovitug aims straight at that dependency. It’s a fully human monoclonal antibody designed to bind to the hepatitis B surface antigen itself — the very protein the delta virus needs to build new copies of itself.

Think of it as cutting the supply line instead of fighting the battle. Without access to the surface antigen, the delta virus can’t assemble, and viral levels fall. The trial’s dual endpoint — lower virus plus normalized liver enzymes — matters because it points to more than less virus in the blood. It points to a liver that’s actually calming down. Notably, Mirum says these results were achieved in a broad patient population, including people with significant liver inflammation, cirrhosis, and clinically significant portal hypertension.

Why this result matters

A genuinely underserved disease

Hepatitis D has historically drawn a fraction of the research attention given to hepatitis B and C. Patients have had very few options, and the disease’s rapid progression means the cost of that neglect is measured in livers — and lives. A single agent that delivers both deep viral suppression and liver-enzyme normalization would be a genuine advance.

The trial results arrived on a day packed with breakthroughs, from a dramatic cliff rescue to an AI system that forecasts from almost no data.

Antibodies as antivirals

The bigger story is the maturation of monoclonal antibodies as antiviral tools. Once confined mostly to cancer and autoimmune disease, engineered antibodies are increasingly being aimed at infectious disease — COVID, RSV, and now hepatitis D. Brelovitug’s success adds momentum to that platform shift.

A realistic timeline

A marketing application in the first half of 2027, if the full data hold up, puts a potential approval inside a plausible two-to-three-year window. Regulators typically take around ten months for a standard review, with faster tracks available for serious conditions with unmet need — and hepatitis D fits that description comfortably.

A note of healthy caution

These are company-reported, top-line results — not yet peer-reviewed or presented in full. Drug development has a long history of promising press releases that looked different under the microscope of full data. The 0% response in the delayed-treatment group is striking, but independent scrutiny at the upcoming medical congress will matter.

That’s not pessimism. It’s how good science works. The signal here is strong enough to be genuinely hopeful about.

The road from trial to treatment

If the full data hold up at the medical congress, the path from here is well mapped but not instant. Watch for the AZURE-4 results later this year — a second pivotal study backing the same registration package — then the FDA filing in the first half of 2027.

For patients, the practical advice is straightforward: if you live with hepatitis B, ask your doctor about delta screening, since hepatitis D can only exist alongside hep B and often goes undiagnosed. And keep expectations calibrated — late-stage trial success is the strongest signal short of approval, but the full peer-reviewed data are still to come.

Key takeaways

• Trial success: Brelovitug met its Phase 3 primary goal — 56% of patients on the 300mg dose saw virus reduction plus normal liver enzymes at 24 weeks, versus 0% without prompt treatment.
• How it works: A fully human monoclonal antibody that binds the hepatitis B surface antigen, starving the delta virus of the protein it needs to replicate.
• Who it helps: People with chronic hepatitis D, a severe liver infection affecting an estimated 230,000 in the U.S. and Europe with few treatment options.
• What’s next: Full data at an upcoming medical congress; AZURE-4 results later this year; FDA application expected in the first half of 2027.
• If this affects you: Talk to a hepatologist about the evolving treatment landscape — and remember this article is information, not medical advice.